closo-Dodecaborate-encapsulating liposomes were developed as boron delivery vehicles for neutron capture therapy. The use of spermidinium as a counter cation of closo-dodecaborates was essential not only for the preparation of high boron content liposome solutions but also for efficient boron delivery to tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c4cc04344h | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A nanocarrier containing carboxylic and histamine groups with dual action: acetylcholine hydrolysis and antidote atropine delivery.
Beilstein J Nanotechnol
January 2025
Alexander Butlerov Institute of Chemistry, Kazan Federal University, Lobachevsky str. 1/29, Kazan 420008, Russia.
Disruption of cholinesterases and, as a consequence, increased levels of acetylcholine lead to serious disturbances in the functioning of the nervous system, including death. The need for rapid administration of an antidote to restore esterase activity is critical, but practical implementation of this is often difficult. One promising solution may be the development of antidote delivery systems that will release the drug only when acetylcholine levels are elevated.
View Article and Find Full Text PDFRecent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer.
Acta Pharm Sin B
December 2024
Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Reactive oxygen species (ROS)-responsive drug delivery systems (DDSs) have garnered significant attention in cancer research because of their potential for precise spatiotemporal drug release tailored to high ROS levels within tumors. Despite the challenges posed by ROS distribution heterogeneity and endogenous supply constraints, this review highlights the strategic alliance of ROS-responsive DDSs with photodynamic therapy (PDT), enabling selective drug delivery and leveraging PDT-induced ROS for enhanced therapeutic efficacy. This review delves into the biological importance of ROS in cancer progression and treatment.
View Article and Find Full Text PDFSmart drug delivery: a DFT study of C fullerene and doped analogs for pyrazinamide.
Nanoscale Adv
December 2024
Department of Chemical Engineering, Sirjan University of Technology Sirjan Iran https://scholar.google.com/citations?user=N6z-rHsAAAAJ&hl=en.
The potential applicability of the C nanocage and its boron nitride-doped analogs (CBN and CBN) as pyrazinamide (PA) carriers was investigated using density functional theory. Geometry optimization and energy calculations were performed using the B3LYP functional and 6-31G(d) basis set. Besides, dispersion-corrected interaction energies were calculated at CAM (Coulomb attenuated method)-B3LYP/6-31G(d,p) and M06-2X/6-31G(d,p) levels of theory.
View Article and Find Full Text PDFPolyethylene glycol complexed with boronophenylalanine as a potential alternative to fructose-boronophenylalanine complexation to increase cellular uptake for BNCT treatment.
Drug Dev Ind Pharm
January 2025
Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Objective: Boron Neutron Capture Therapy (BNCT) is a novel precision radiotherapy. The key to BNCT application lies in the effective targeting and retention of the boron-10 (B) carrier. Among the various compounds studied in clinical settings, 4-boronophenylalanine (BPA) become the most prevalent one currently.
View Article and Find Full Text PDFSynthesis of New Promising BNCT Agents Based on Conjugates of -Dodecaborate Anion and Aliphatic Diamino Acids.
Int J Mol Sci
December 2024
Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Leninskii Pr. 31, 119991 Moscow, Russia.
In this work, a series of boronated amidines based on the -dodecaborate anion and amino acids containing an amino group in the side chain of the general formula [BHNHC(NH(CH)CH(NH)COOH)CH], where n = 2, 3, 4, were synthesized. These derivatives contain conserved α-amino and α-carboxyl groups recognized by the binding centers of the large neutral amino acid transporter (LAT) system, which serves as a target for the clinically applied BNCT agent para-boronophenylalanine (BPA). The paper describes several approaches to synthesizing the target compounds, their acute toxicity studies, and tumor uptake studies in vivo in two tumor models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!